Figure 1

From: Rituximab maintenance therapy after autologous stem cell transplantation prolongs progression-free survival in patients with mantle cell lymphoma

Figure 1

Landmark analysis of (a) progression-free survival and (b) overall survival calculated from the 6-month landmark after autoSCT for patients with MCL who underwent autoSCT and received rituximab maintenance therapy (n=20, dotted line) or no further treatment (n=38, solid line). The time is reported in months.